Disposable Bioreactors: The Next Generation - - BioPharm International


Disposable Bioreactors: The Next Generation

BioPharm International
Volume 21, Issue 4


What has led to the rapid adoption of the large-scale bioreactors over the last two years? Jon Reid's view is that biopharmaceutical manufacturing is a conservative market and is used to the stainless-steel configuration. The more similar the bioreactor configuration, instrumentation, and control systems are to the stainless-steel bioreactor, the greater will be the acceptance. The ready acceptance of the SUB and XDR may be because their height to diameter ratios are similar to their stainless-steel counterparts, and both use conventional instrumentation. The SUB differs from the XDR in that the SUB has a mechanically linked agitator compared to the XDR's magnetically coupled unit. The mechanically coupled agitator provides scope for precise positioning of the impellor and the option to go for different designs in the drive to improve heat and mass transfer.


So what's important from the user's perspective and where are the challenges? According to a recent presentation at the ISPE 2008 Conference on Manufacturing Excellence by Dave Wareheim, engineering fellow at Centocor, users want similar geometries to stainless-steel bioreactors with good mixing, gas distribution, and heating and cooling.

To date, disposable bioreactors have primarily been used in cell cultures. The shift in their usage in microbial or yeast systems will not be easy and will require significant technical advances. Going forward, bioreactor volume will probably not increase much above 2,000 L; both Xcellerex and Thermo Fisher have stated that this is the limit for the foreseeable future. The maximum working volume for the Wave is 500 L. Technical improvements are required in mixing, sparging, and heating and cooling of the current models. These are essential to meet the demands of the high-titer processes, especially at larger volumes. At present, the instrumentation used is based on conventional probes. It is expected that these will be replaced by disposable sensors. There will be a large number of new entrants into this market followed by a consolidation. Disposable bioreactors will become the dominant technology in biomanufacturing operations. Their adoption is being driven by two trends—reduced manufacturing costs and the development of high-titer processes. Given the conservative nature of our industry and the requirements of scale-up and scale-down, disposable technologies that mimic the conventional stainless-steel bioreactor will be most readily adopted.

Andrew Sinclair is the managing director at Biopharm Services, Chesham, Bucks, UK, +44 (0) 1494 793 243,

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here